Biotech News
NewAmsterdam Pharma Reports Full Year 2025 Financial Results and Provides Corporate Update
ir.newamsterdampharma.com2026-05-06 14:53 EST
-- Approval decisions from EMA, UK and Switzerland regulators for obicetrapib and obicetrapib/ezetimibe fixed dose combination expected in 2H26 -- -- Phase 3 PREVAIL CVOT blinded event rate tracking in line with observed event rate in BROADWAY-- -- Topline data from RUBENS Phase 3 trial in